A green comet likely is breaking apart and won't be visible to the naked eye
NEW YORK (AP) — A newly discovered green comet tracked by telescopes has likely broken apart as it swung by the sun, dashing hopes of a naked-eye spectacle.
Comet SWAN, hailing from the Oort Cloud beyond Pluto, has been visible through telescopes and binoculars over the past few weeks with its streaming tail, but experts said it may not have survived its recent trip past the sun and is fading fast.
'We'll soon be left with just a dusty rubble pile,' astrophysicist Karl Battams with the U.S. Naval Research Laboratory said in an email.
Comets are balls of frozen gas and dust from billions of years ago. Every so often, a comet passes through the inner solar system.
'These are relics from when the solar system first formed,' said Jason Ybarra, director of the West Virginia University Planetarium and Observatory.
The newest comet was discovered by amateur astronomers, who spied it in photos taken by a camera on a spacecraft operated by NASA and the European Space Agency to study the sun.
The comet won't swing close to Earth like Tsuchinshan-Atlas did last year. Other notable flybys included Neowise in 2020 and Hale-Bopp and Hyakutake in the 1990s.
The comet, also designated C/2025 F2, would have been visible just after dark slightly north of where the sun set. Its green color would have been difficult to see with the naked eye.
This might have been the object's first ever trip past the sun, making it particularly vulnerable to breaking apart, Battams said. After its flyby, what's left of the comet will disappear into the outer reaches of the solar system, past where scientists think it came from.
'It's going to go so far out that we have no idea if it's ever going to return,' said Battams.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
11 hours ago
- New York Post
Japanese lunar lander falls silent while attempting a moon touchdown
A private lunar lander from Japan fell silent while descending to the moon with a mini rover Friday and its fate was unknown. The Tokyo-based company ispace said its lander dropped out of lunar orbit as planned and everything seemed to be going well. But there was no immediate word on the outcome, following the hourlong descent. As the tension mounted, the company's livestream of the attempted landing came to an abrupt end. 'We haven't been able to confirm,' one of the commentators said in Japanese, but Mission Control 'will continuously attempt to communicate with the lander.' Advertisement 4 This image taken from video shows flight controllers at ispace Mission Control in Tokyo awaiting confirmation of their private lunar lander touching down on the moon Friday, June 6, 2025. AP The encore came two years after the company's first moonshot ended in a crash landing, giving rise to the name Resilience for its successor lander. Resilience carried a rover with a shovel to gather lunar dirt as well as a Swedish artist's toy-size red house for placement on the moon's dusty surface. Long the province of governments, the moon became a target of private outfits in 2019, with more flops than wins along the way. Advertisement Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the moon faster and became the first private entity to successfully land there in March. Another U.S. company, Intuitive Machines, arrived at the moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the moon's south pole and was declared dead within hours. Resilience was targeting the top of the moon, a less forbidding place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. 4 A replica of lunar rover Tenacious (front) and Resilience, a moon lander built by Japan-based startup ispace, displayed at a live event for the progress of the Moon landing of Resilience, in Tokyo, Japan, early 06 June 2025. FRANCK ROBICHON/EPA-EFE/Shutterstock Advertisement Plans had called for the 7.5-foot (2.3-meter) Resilience to beam back pictures within hours and for the lander to lower the piggybacking rover onto the lunar surface this weekend. Made of carbon fiber-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sported a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for NASA. The rover, weighing just 11 pounds (5 kilograms), was going to stick close to the lander, going in circles at a speed of less than one inch (a couple centimeters) per second. It was capable of venturing up to two-thirds of a mile (1 kilometer) from the lander and should be operational throughout the two-week mission, the period of daylight. Besides science and tech experiments, there was an artistic touch. Advertisement 4 Employees of 'ispace' react as they wait for the signal from the touchdown of its lunar lander Resilience on the Moon at a venue to watch its landing in Tokyo, Japan, June 6, 2025. REUTERS The rover held a tiny, Swedish-style red cottage with white trim and a green door, dubbed the Moonhouse by creator Mikael Genberg, for placement on the lunar surface. Takeshi Hakamada, CEO and founder of ispace, considered the latest moonshot 'merely a steppingstone,' with its next, much bigger lander launching by 2027 with NASA involvement, and even more to follow. Minutes before the attempted landing, Hakamada assured everyone that ispace had learned from its first failed mission. 'Engineers did everything they possibly could' to ensure success this time, he said. Chief financial officer Jumpei Nozaki promised to continue the lunar quest regardless of the outcome. 4 Takeshi Hakamada, 'ispace' founder and chief executive officer, reacts as he waits with employees for the signal from the touchdown of its lunar lander Resilience on the Moon at a venue to watch its landing in Tokyo, Japan, June 6, 2025. REUTERS Ispace, like other businesses, does not have 'infinite funds' and cannot afford repeated failures, Jeremy Fix, chief engineer for ispace's U.S. subsidiary, said at a conference last month. While not divulging the cost of the current mission, company officials said it's less than the first one which exceeded $100 million. Advertisement Two other U.S. companies are aiming for moon landings by year's end: Jeff Bezos' Blue Origin and Astrobotic Technology. Astrobotic's first lunar lander missed the moon altogether in 2024 and came crashing back through Earth's atmosphere. For decades, governments competed to get to the moon. Only five countries have pulled off successful robotic lunar landings: Russia, the U.S., China, India and Japan. Of those, only the U.S. has landed people on the moon: 12 NASA astronauts from 1969 through 1972. NASA expects to send four astronauts around the moon next year. That would be followed a year or more later by the first lunar landing by a crew in more than a half-century, with SpaceX's Starship providing the lift from lunar orbit all the way down to the surface. China also has moon landing plans for its own astronauts by 2030.
Yahoo
13 hours ago
- Yahoo
A private Japanese spacecraft falls silent while trying to land on the moon, company officials say
TOKYO (AP) — A private Japanese spacecraft falls silent while trying to land on the moon, company officials say.
Associated Press
14 hours ago
- Associated Press
Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance
WASHINGTON (AP) — There was a notable absence last week when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced in a 58-second video that the government would no longer endorse the COVID-19 vaccine for healthy children or pregnant women. The director of the Centers for Disease Control and Prevention — the person who typically signs off on federal vaccine recommendations — was nowhere to be seen. The CDC, a $9.2 billion-a-year agency tasked with reviewing life-saving vaccines, monitoring diseases and watching for budding threats to Americans' health, is without a clear leader. 'I've been disappointed that we haven't had an aggressive director since — February, March, April, May — fighting for the resources that CDC needs,' said Dr. Robert Redfield, who served as CDC director under the first Trump administration and supported Kennedy's nomination as the nation's health secretary. $9.2 billion-a-year agency without leader as nomination awaits The leadership vacuum at a foremost federal public health agency has existed for months, after President Donald Trump suddenly withdrew his first pick for CDC director in March. A hearing for his new nominee — the agency's former acting director Susan Monarez — has not been scheduled because she has not submitted all the paperwork necessary to proceed, according to a spokesman for Sen. Bill Cassidy, R-La., who will oversee the nomination. HHS did not answer written questions about Monarez's nomination, her current role at the CDC or her salary. An employee directory lists Monarez, a longtime government employee, as a staffer for the NIH under the Advanced Research Projects Agency for Health. Redfield described Kennedy as 'very supportive' of Monarez's nomination. Instead, a lawyer and political appointee with no medical experience is 'carrying out some of the duties' of director at the agency that for seven decades has been led by someone with a medical degree. Matthew Buzzelli, who is also the chief of staff at the CDC, is 'surrounded by highly qualified medical professionals and advisors to help fulfill these duties as appropriate,' Andrew Nixon, an HHS spokesperson said in a statement. Adding to the confusion was an employee-wide email sent last week that thanked 'new acting directors who shave stepped up to the plate.' The email, signed by Monarez, listed her as the acting director. It was was sent just days after Kennedy said at a Senate hearing that Monarez had been replaced by Buzzelli. The lack of a confirmed director will be a problem if a public health emergency such as the COVID-19 pandemic or a rapid uptick in measles cases hits, said Michael Osterholm, an epidemiologist at the University of Minnesota. 'CDC is a crisis, waiting for a crisis to happen,' said Osterholm. 'At this point, I couldn't tell you for the life of me who was going to pull what trigger in a crisis situation.' An acting director rarely seen, and stalled decisions At CDC headquarters in Atlanta, employees say Monarez was rarely heard from between late January – when she was appointed acting director – and late March, when Trump nominated her. She also has not held any of the 'all hands' meetings that were customary under previous CDC chiefs, according to several staffers. One employee, who insisted on anonymity because they were not authorized to speak to the media and fears being fired if identified said Monarez has been almost invisible since her nomination, adding that her absence has been cited by other leaders as an excuse for delaying action. The situation already has led to confusion. In April, a 15-member CDC advisory panel of outside experts met to discuss vaccine policy. The panel makes recommendations to the CDC Director, who routinely signs off on them. But it was unclear during the meeting who would be reviewing the panel's recommendations, which included the expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. HHS officials said the recommendations were going to Buzzelli, but then weeks passed with no decision. A month after the meeting ended, the CDC posted on a web site that Kennedy had signed off on recommendations for travelers against chikungunya, a viral disease transmitted to humans by mosquitos. But there continues to be no word about a decision about the other vaccine recommendations. Controversial COVID-19 vaccine recommendations bypassed CDC panel The problem was accentuated again last week, when Kennedy rolled out recommendations for the COVID-19 vaccine saying they were no longer recommended for healthy children or pregnant women, even though expectant mothers are considered a high-risk group if they contract the virus. Kennedy made the surprise announcement without input from the CDC advisory panel that has historically made recommendations on the nation's vaccine schedule. The CDC days later posted revised guidance that said healthy kids and pregnant women may get the shots. Nixon, the HHS spokesman, said CDC staff were consulted on the recommendations, but would not provide staffer's names or titles. He also did not provide the specific data or research that Kennedy reviewed to reach his conclusion on the new COVID-19 recommendations, just weeks after he said that he did not think 'people should be taking medical advice' from him. 'As Secretary Kennedy said, there is a clear lack of data to support the repeat booster strategy in children,' Nixon said in a statement. Research shows that pregnant women are at higher risk of severe illness, mechanical ventilation and death, when they contract COVID-19 infections. During the height of the pandemic, deaths of women during pregnancy or shortly after childbirth soared to their highest level in 50 years. Vaccinations also have been recommended for pregnant women because it passes immunity to newborns who are too young for vaccines and also vulnerable to infections. Nixon did not address a written question about recommendations for pregnant women. Kennedy's decision to bypass the the advisory panel and announce new COVID-19 recommendations on his own prompted a key CDC official who works with the committee – Dr. Lakshmi Panagiotakopoulos – to announce her resignation last Friday. 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in an email seen by an Associated Press reporter. Signs are mounting that the CDC has been 'sidelined' from key decision-making under Kennedy's watch, said Dr. Anand Parekh, the chief medical adviser for The Bipartisan Policy Center. 'It's difficult to ascertain how we will reverse the chronic disease epidemic or be prepared for myriad public health emergencies without a strong CDC and visible, empowered director,' Parekh said. 'It's also worth noting that every community in the country is served by a local or state public health department that depends on the scientific expertise of the CDC and the leadership of the CDC director.'
